Remus Pharmaceuticals Q4 Results
- BSE: -
- NSE: REMUS
- ISIN: INE0O5T01011
- Sector: Biotechnology & Drugs
BSE
This stock is not traded on BSE
NSE
695.05
12.25 (1.79%)
12.25 (1.79%)Volume2.50 K
Updated: Fri 12 Jun, 2026 | 15:23:35
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
- Total Income₹453.43 Cr.(30.42%)
- Operating Profit₹28.33 Cr.(19.57%)
- Profit After Tax₹19.49 Cr.(29.43%)
- Operating Margin6.25%(-36.56%)
Note: Comparison is on YoY basis
Quarterly - Remus Pharmaceuticals Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 26 | Dec 22 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 425.10 | 24.78 | N/A | 165.39 | 31.21% |
| Depreciation/ Amortization | 1.47 | 0.33 | N/A | 0.48 | -1.31% |
| Operating Income | 28.33 | 7.61 | N/A | 18.07 | 19.57% |
| Net Income | 19.49 | 6.44 | N/A | 15.89 | 29.43% |
| Other Operating Expenses Total | 24.36 | 0.00 | N/A | 10.06 | 70.96% |
| Net Income Before Taxes | 31.26 | 8.69 | N/A | 21.42 | 24.71% |
| Total Revenue | 453.43 | 32.39 | N/A | 183.46 | 30.42% |
| Selling/ General/ Admin Expenses Total | 6.60 | 9.12 | N/A | 4.13 | -8.64% |
| Diluted Normalized EPS | 20.86 | 5.47 | N/A | 13.48 | 63.24% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.